Refractory pruritus responds to dupilumab in a patient with TTC7A mutation
- PMID: 33457482
- PMCID: PMC7797900
- DOI: 10.1016/j.jdcr.2020.12.004
Refractory pruritus responds to dupilumab in a patient with TTC7A mutation
Keywords: IL, interleukin; MIA, multiple intestinal atresia; TTC7A mutation; TTC7A, tetratricopeptide repeat domain 7A; chronic pruritus; combined immune deficiency; dupilumab; eczematous lesions; ichthyosis; multiple intestinal atresia; xerosis.
Conflict of interest statement
Dr Danielle Marcoux has been primary investigator, speaker, and on advisory board for Sanofi Genzyme. Drs Yassaman Alipour Tehrany, Louis Marois, Caroline Colmant, Valérie Marchand, Victor Kokta, Jérôme Coulombe, Elie Haddad, and Catherine McCuaig have no conflicts of interest to declare.
Figures
References
-
- Leclerc-Mercier S., Lemoine R., Bigorgne A.E. Ichthyosis as the dermatological phenotype associated with TTC7A mutations. Br J Dermatol. 2016;175:1061–1064. - PubMed
-
- Nüesch U., Mauracher A.A., Opitz L. Epithelial proliferation in inflammatory skin disease is regulated by tetratricopeptide repeat domain 7 (Ttc7) in fibroblasts and lymphocytes. J Allergy Clin Immunol. 2019;143:292–304.e8. - PubMed
-
- Fayard J., Collardeau S., Bertrand Y. TTC7A mutation must be considered in patients with repeated intestinal atresia associated with early inflammatory bowel disease: two new case reports and a literature review. Arch Pediatr. 2018;25:334–339. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources